In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- National HIV testing day is Saturdayon June 25, 2020 at 9:00 pm
Saturday, June 27, is National HIV Testing Day to encourage people to get tested for HIV, know their status, and get linked to care and treatment. The Cabell-Huntington ...
- HHS eases organ donation restrictions on HIV, hepatitis-infected donorson June 25, 2020 at 4:41 pm
HHS on Thursday recommended removing some terms from its organ transplant guidelines that specifically characterize donors with HIV, and hepatitis B or C as a higher health risks in an effort to ...
- COVID must not divert us from HIV and hepatitis eliminationon June 25, 2020 at 4:00 pm
COVID is also disrupting medical care across the country. The health sector lost 1.4 million jobs in April as outpatient care dried up. Oncologists are switching to oral treatments, surgeons are ...
- Facts About In-Home HIV Testingon June 25, 2020 at 1:24 pm
HIV screening is key to controlling the virus. If people can’t get to a clinic for testing, or have concerns about their privacy, there is a home testing kit that has been evaluated and approved by ...
- How to find free or low-cost HIV testing and treatmenton June 25, 2020 at 11:40 am
If you’ve had sex with a person who’s had sex with another, different person, you should be tested for HIV infection,” said Dr. Laura W. Cheever, Sc.M., physician and associate administrator at the ...
- Greater Than AIDS, With Support From Walgreens and OraSure Technologies, to Provide 10,000 Free In-Home HIV Tests to Community Partnerson June 25, 2020 at 9:52 am
With in-person health services limited due to COVID-19, Greater Than AIDS, a public information initiative of KFF, and Walgreens today announced a new program to provide 10,000 OraQuick® In-Home HIV ...
- Being a Gay, HIV-Positive Mayor of a Small Town: A New Film Documents the Founder of POZ Magazine’s Storyon June 25, 2020 at 9:03 am
POZ and Sero Project founder Sean Strub’s story as mayor of Milford, Pennsylvania, is showcased in a new documentary.
- Watch Elton John and Jonathan Van Ness Discuss HIV Activismon June 25, 2020 at 7:40 am
Sir Elton John and Queer Eye grooming expert Jonathan Van Ness talk about living with HIV/AIDS and the fight to find a cure on the latest installment of Instagram’s Advocates series. “I’m in a ...
- Germany ramps up its contribution to the HIV response with an extra €20 million to UNAIDSon June 25, 2020 at 4:59 am
English News and Press Release on World about Contributions, HIV/Aids and Epidemic; published on 25 Jun 2020 by UNAIDS ...
- Jacksonville nonprofit offers free HIV testing and educationon June 24, 2020 at 12:33 pm
On June 27 the Jacksonville Health and Educational Resource Center will offer HIV testing and educational sessions in the hopes of better health outcomes ...
via Google News and Bing News